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ABSTRACT 
Objective: Due to quality of generic formulations depends on available information of reference drug products the aim of this work was to perform 
an in vitro dissolution study of two doses of propranolol-HCl and ranitidine-HCl reference tablets using USP basket or paddle apparatus and flow-
through cell method. 
Methods: Two doses of propranolol-HCl (10-mg and 80-mg) and ranitidine-HCl (150-mg and 300-mg) of Mexican reference products were used. 
Dissolution profiles of propranolol-HCl were obtained with USP basket apparatus at 100 rpm and 1000 ml of 1% hydrochloric acid. Profiles of 
ranitidine-HCl were determined with USP paddle apparatus at 50 rpm and 900 ml of distilled water. All formulations were also studied with the 
flow-through cell method using laminar flow at 16 ml/min. Dissolution profiles were compared by model-independent (f2 similarity factor, mean 
dissolution time and dissolution efficiency) and model-dependent methods (dissolution data adjusted to some mathematical equations). Time data, 
derived from these adjustments, as t50%, t63.25%, and t85%
Results: With all approaches used and being high solubility drugs significant differences were found between low and high doses and between USP 
dissolution apparatuses (*P<0.05). 
 were used to compare dissolution profiles. 
Conclusion: In vitro dissolution performance of two doses of propranolol-HCl and ranitidine-HCl was not expected. Considering the same USP 
dissolution apparatus, the reference tablets did not allow the simultaneous release of the used doses. The results could be of interest for pharmaceutical 
laboratories or health authorities that classify some drug products as a reference to be used in dissolution and bioequivalence studies
Keywords: Flow-through cell method, Propranolol-HCl tablets, Ranitidine-HCl tablets, Reference drug products, USP basket apparatus, USP paddle 
apparatus 
. 




Propranolol is a non-selective β-adrenergic receptor-blocking agent. 
It is used to treat high blood pressure (hypertension) and severe 
infantile hemangioma [1]. Due to propranolol short biological half-
life (3-5 h), it needs to be administered in two or three doses of 40 to 
80 mg per day [2]. Ranitidine-HCl is a H2 receptor antagonist used in 
the treatment of gastric and duodenal ulceration and gastro-
oesophageal reflux disease. It is absorbed from the gastrointestinal 
tract with the bioavailability of about 50% and an elimination half-
life of 3 h [3]
 




1: Chemical structures of propranolol-HCl (A) and 
ranitidine-HCl (B) 
Propranolol-HCl and ranitidine-HCl are included in the WHO Model 
List of Essential Medicines [4], and because of its wide use, these 
drugs are manufactured as generic formulations. This kind of 
formulations offer savings for patients, hospitals and pharmaceutical 
laboratories. Generic formulations should be evaluated periodically 
to ensure a similar therapeutic effect to that of the reference, so 
quality of generic formulations depends on the quality of reference 
drug products. In vitro dissolution studies are important to know the 
dissolution performance of reference products considering factors 
as dose and hydrodynamics. 
According to the Biopharmaceutics Classification System (BCS), 
propranolol is a class I drug (high solubility/high permeability) [5]. 
Solubility of propranolol-HCl in water is reported as 1 g in 10-30 ml [6]. 
Ranitidine-HCl is a class III drug (high solubility/low permeability). 
Solubility of ranitidine-HCl in water is 660 mg/ml [7]. For propranolol-
HCl, solubility within the physiological pH is not critical, so the 
dissolution rate of the formulation will be the decisive factor for its 
bioavailability [6]. For class I drugs, the dissolution of more than 85% at 
30 min makes the comparison of dissolution profiles between reference 
and test (generic) formulation unnecessary [8]
Official d
. 
issolution tests for propranolol-HCl and ranitidine-HCl tablets 
are described in United States Pharmacopoeia (USP) [9] and Mexican 
Pharmacopoeia [10]. Dissolution conditions for propranolol-HCl include 
USP basket apparatus (USP Apparatus 1) at 100 rpm and 1000 ml of 1% 
hydrochloric acid at 37.0±0.5 °C as dissolution medium. Under these 
conditions, not less than 75% of drug should be dissolved in 30 min (Q ≥ 
75%). Dissolution conditions for ranitidine-HCl include USP paddle 
apparatus (USP Apparatus 2) at 50 and 900 ml of distilled water at 
37.0±0.5 °C. Not less than 80% should be dissolved at 45 min (Q ≥ 80%). 
Biowaiver monographs for propranolol-HCl [6] and ranitidine-HCl [7] 
have been published suggesting the replacing of in vivo studies for in 
vitro dissolution studies. 
Additional dissolution tests to those established with USP vessels 
apparatus (USP Apparatus 1 or 2) have been developed with flow-
through cell method (USP Apparatus 4). Its advantages over 
conventional USP basket and paddle apparatuses have been widely 
demonstrated, especially with dissolution of poorly soluble drugs 
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[11, 12]. The flow-through cell method has a continuous extraction 
of the drug, simulating the absorption into the systemic circulation, 
by generating intermittent flow of dissolution medium inside the 
compartment where the dosage form is placed [13]. The USP 
Apparatus 4 better simulates the hydrodynamic environment found 
in the gastrointestinal tract. Previous reports show that in vitro data 
obtained with flow-through cell method better reflect in vivo 
performance of some drugs [14, 15]. Despite the advantages of USP 
Apparatus 4, information about dissolution performance of 
propranolol-HCl and ranitidine-HCl reference tablets is scarce. 
A comparative dissolution study of metronidazole with reference and 
generic formulations has been published [16]. In the study, two doses of 
metronidazole tablets and two USP dissolution apparatuses were used 
and significant differences in dissolution profiles of metronidazole from 
reference formulation were found. For this antimicrobial drug a 
biowaiver monograph has also been published [17]. For its high 
solubility and dissolution conditions used no problem should present the 
in vitro dissolution of both metronidazole doses however, its dissolution 
performance was not as expected. Daousani and Macheras [18], based 
on a previous analysis of theoretical and experimental data, established 
the drug dose as an important parameter for drug dissolution and 
biopharmaceutic drug classification. 
The main objective of this in vitro release study was to evaluate the 
dissolution performance of propranolol-HCl and ranitidine-HCl 
reference tablets using two doses of each drug and two dissolution 
apparatuses. The results could be of interest for pharmaceutical 
laboratories or health authorities that classify some drug products 
as a reference to be used in dissolution and bioequivalence studies. 
MATERIALS AND METHODS 
Materials 
Propranolol-HCl (Inderalici®, 10-mg and 80-mg, AstraZeneca SA de 
CV) and ranitidine-HCl (Azantac®, 150-mg and 300-mg, Grimann SA 
de CV) tablets were used. Mexican health regulatory agency 
COFEPRIS has established both drug products as a reference to be 
used in bioequivalence studies [19]. Hydrochloric acid and methanol 
analytical grade were purchased from J. T. Baker-Mexico. 
Propranolol-HCl and ranitidine-HCl standard were purchased from 
Sigma-Aldrich Co. (St. Louis MO, USA). 
Content uniformity and assay 
Content uniformity and assay tests with all reference formulations 
were performed according to the procedures described in US 
Pharmacopeia [9]. 
Dissolution profiles 
USP vessels apparatus 
Dissolution profiles of propranolol-HCl and ranitidine-HCl were 
determined according to USP tests [9] using an automated USP 
vessels apparatus (Sotax AT-7 Smart, Switzerland) with a piston 
pump (Sotax CY7-50, Switzerland). An UV/Vis spectrophotometer 
with 1-mm flow cells (Perkin Elmer Lambda 35, USA) was used. All 
equipment and data generated were controlled by specific software 
designed by Sotax. Dissolution profiles of propranolol-HCl tablets 
were determined with USP Apparatus 1 at 100 rpm. Tablets were 
sprinkled on 1000 ml of 1% hydrochloric acid. Dissolution profiles 
of ranitidine-HCl were obtained with USP Apparatus 2 at 50 rpm. 
Tablets were sprinkled on 900 ml of distilled water. Temperature of 
dissolution media was 37.0±0.5 °C. Sequential sampling using 0.45 
µm nitrocellulose filters (Millipore®) occurred over 30 min 
(propranolol-HCl) or 45 min (ranitidine-HCl) at regular 5-min 
intervals with 12 replicates. The amount of propranolol-HCl and 
ranitidine-HCl dissolved was determined with standard calibration 
curves at 289 and 314 nm, respectively. 
Dissolution profiles of propranolol-HCl and ranitidine-HCl were 
obtained in an automated USP Apparatus 4 (Sotax CE6, Sotax AG, 
Switzerland) with 22.6-mm cells (i.d.) and a piston pump (Sotax CY7-
50, Sotax AG, Switzerland). Laminar flow (with a bed of 6 g of glass 
beads) was used. The degassed dissolution media at 37.0±0.5 °C, 1% 
hydrochloric acid and distilled water, were pumped at 16 ml/min. An 
open system was used without recycling the dissolution media. 
Sequential sampling using nitrocellulose filters was set at regular 5-
min intervals over 30 or 45 min, with 12 replicates. The amount of 
propranolol-HCl and ranitidine-HCl dissolved was determined in a 
UV/Vis spectrophotometer with 1-mm cells (Perkin Elmer Lambda 10, 
USA) at 289 and 314 nm, respectively. For every trial, a standard 
calibration curve was prepared. 
Flow-through cell method 
Dissolution data analysis 
Dissolution profiles of propranolol-HCl and ranitidine-HCl were 
compared by model-independent and model-dependent approaches. 
For the first kind of comparison, f 2 similarity factor was calculated 
according to equation 1 [20]: 
f2 = 50 × log {[1 + (
1
n
) ∑ �Rj − Tj�
2n
j=1 ]−0.5} × 100 Eq. [1] 
Where n is the number of time points used to evaluate the amount of 
drug dissolved, Rj and Tj are the average percentages of drug dissolved 
at a j specific time from reference and test products, respectively. 
Similar dissolution profiles were found when f2 = 50-100 [20]. Then, 
dissolution profiles were compared with the following model-
independent parameters: percentage of drug dissolved at last 
sampling time (Q criterion), mean dissolution time (MDT) and 
dissolution efficiency (DE). Q value is a quality pharmacopeial 
criterion used to compare the extent of drug dissolved (batch-to-
batch or after some modifications of the manufacturing process) [9]. 
MDT is the time necessary to dissolve 63.2% of drug and it is 
calculated with statistical moment’s theory [21]. DE is the area 
under the dissolution curve up to a certain time, t, expressed as a 
percentage of the area of the rectangle described by 100% 
dissolution over the same time [22]. MDT and DE are commonly 
used parameters to IVIVC level B and C, respectively [23]. 
 
For model-dependent comparisons, dissolution data of propranolol-
HCl and ranitidine-HCl formulations were fitted to Hyperbole, 
Higuchi, Korsmeyer-Peppas, Hixson-Crowell, Makoid-Banakar, 
Weibull, Logistic, and Gompertz model. Mathematical equations of 
all models (excepting Hyperbole model) were described by Zhang et 
al. [24] and are shown in table 1. 
Table 1: Mathematical equations used to fit dissolution data 




 Makoid-Banakar 𝐹𝐹 = 𝑘𝑘𝑀𝑀𝑀𝑀 ∙ 𝑡𝑡
𝑛𝑛 ∙ 𝑒𝑒−𝑘𝑘𝑡𝑡  





Korsmeyer-Peppas 𝐹𝐹 = 𝑘𝑘𝐾𝐾𝐾𝐾 ∙ 𝑡𝑡𝑛𝑛  Logistic 𝐹𝐹 = 100 ∙
𝑒𝑒𝛼𝛼−𝛽𝛽 ∙𝑙𝑙𝑙𝑙𝑙𝑙 (𝑡𝑡)
1 − 𝑒𝑒𝛼𝛼+𝛽𝛽 ∙𝑙𝑙𝑙𝑙𝑙𝑙 (𝑡𝑡)
 
Hixson-Crowell 𝐹𝐹 = 100[1 − (1 − 𝑘𝑘𝐻𝐻𝐻𝐻 ∙ 𝑡𝑡)3] Gompertz 𝐹𝐹 = 100 ∙ 𝑒𝑒−𝛼𝛼 ∙𝑒𝑒−𝛽𝛽 ∙𝑙𝑙𝑙𝑙𝑙𝑙 (𝑡𝑡) 
 
Dissolution data were adjusted to hyperbole equation with SigmaPlot 
software (version 11.0) and t50%, t63.2%, and t85% values were calculated 
after adjustment to this mathematical equation. For the rest of the 
adjustments, the model with the highest determination coefficient 
(R2adjusted) and the minimum Akaike Information Criterion (AIC) was 
chosen as the best fit model [25]. f2, MDT, DE, and adjustment to all 
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models (excepting hyperbole) was calculated with Excel add-in 
DDSolver program [24]. Mean values were compared by a Student’s t-
test and significant differences were considered if *P<0.05. 
RESULTS AND DISCUSSION 
Content uniformity and assay 
All formulations were within USP limits. The percentages of 
propranolol-HCl and ranitidine-HCl on the content uniformity tests 
ranged from 85-115% and the assay tests between 90-110%. 
Results are shown in table 2. 
Dissolution profiles 
Model-independent comparisons 
Dissolution profiles of propranolol-HCl and ranitidine-HCl from 
reference formulations, obtained with USP basket or paddle 
apparatus and flow-through cell method, 
 
are shown in fig. 2. 
Table 2: Content uniformity and assay results, n = 10*; mean±SD, n = 3† 
Drug Dose Content uniformity (min-max%)* Assay (%)† 
P Low 95.27-110.68 106.34±1.72 
High 101.15-108.45 97.78±1.86 
R Low 101.96-107.95 101.84±4.65 





2: Dissolution profiles of propranolol-HCl and ranitidine-HCl from reference formulations, the dotted line shows 85% of drug 
dissolved. mean±SD, n = 12 
Table 3: Model-independent and-dependent parameters of propranolol-HCl (P) and ranitidine-HCl (R). mean±SEM, n = 12. *P<0.05, Low 
vs. High dose 
Drug/Dose Diss. at last sampling time (%) MDT(min) DE (%) t50% t (min) 63.2% t (min) 85% (min) 
USP vessels apparatus 
P/low 107.49±1.49 14.27±0.15 56.33±0.86 13.08±0.23 16.76±0.28 23.08±0.35 
P/High 89.68±1.64* 15.80±0.18* 42.42±0.76* 17.33±0.32* 21.94±0.41* 29.60±0.57* 
R/low 105.72±0.87 13.60±0.37 73.76±1.12 10.17±0.45 14.37±0.57 24.04±0.77 
R/High 105.57±0.64 8.87±0.09* 84.77±0.57* 5.18±0.11* 7.84±0.17* 15.67±0.34* 
Flow-through cell method 
P/low 78.41±1.77 15.72±0.16 37.27±0.64 19.73±0.35 24.91±0.45 33.44±0.62 
P/High 75.69±2.36 17.39±0.23* 31.65±0.66* 22.12±0.58* 27.96±0.74* 37.61±0.99* 
R/low 101.20±1.20 13.40±0.26 71.00±0.53 11.37±0.18 15.84±0.21 25.69±0.35 
R/High 77.51±1.45* 13.93±0.16 53.50±0.99* 17.30±0.58* 25.30±0.89* 46.09±1.94* 
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All formulations met the pharmacopeial Q criterion (Q ≥ 75% for 
propranolol-HCl and Q ≥ 80% for ranitidine-HCl), excepting high 
dose of ranitidine-HCl with flow-through cell apparatus (Q = 
77.51%). Specific data and comparison of drug dissolved at the last 
sampling time are shown in table 3. 
It is important to highlight the lack of compliance of Q criterion of a 
high dose of ranitidine-HCl with flow-through cell method. Dose, the 
total volume of dissolution medium and high solubility should be 
factors that favor ranitidine-HCl dissolution however, this does not 
happen. Something similar is observed with the dissolution of both 
drugs at 15 and 30 min. A very rapid drug dissolution can be 
achieved if ≥  85% drug is dissolved in 15 min [26] and rapid drug 
dissolution can be achieved if the same percentage of drug is 
reached in 30 min [27]. More than 85% of drug dissolved at 15 min 
is reached only by a high dose of ranitidine-HCl in USP paddle 
apparatus. More than 85% of drug dissolved at 30 min is reached by 
both doses of propranolol-HCl in USP basket apparatus, both doses 
of ranitidine-HCl in USP paddle apparatus and a low dose of 
ranitidine-HCl with flow-through cell method. Under dissolution 
conditions used, reference formulations should allow the complete 
release of both drugs, however, as previously mentioned, the high 
solubility of each drug and the volume of dissolution media are not 
enough factors to obtain the extent of dissolution that characterizes 
a drug product with very rapid or rapid dissolution. 
As observed, with flow-through cell method the used formulations 
showed slower dissolution rates than that found with USP basket or 
paddle apparatus. Langenbucher et al. [28] stated that this kind of 
behavior can be explained by the hydrodynamic conditions 
generated by USP Apparatus 4, where there are no agitation 
mechanisms and the dosage form and drug particles are 
continuously exposed to a uniform laminar flow, similar to the 
natural environment of the gastrointestinal tract, causing a different 
dissolution pattern. With flow-through cell method, cell size, glass 
beads and flow rate are critical factors to form this special pattern. 
In this in vitro release study of propranolol-HCl and ranitidine-HCl 
flow rate of 16 ml/min was used because it is one of the three 
suggested by European and United States Pharmacopeias [29]. 
To compare dissolution profiles of low vs. high dose of propranolol-
HCl and ranitidine-HCl f2
 
 similarity factors were calculated. 
Additionally, USP vessels apparatus vs. flow-through cell method 
was also compared. Results are shown in table 4. 
Table 4: f2 similarity factor calculated to compare dissolution profiles of propranolol-HCl (P) and ranitidine-HCl (R) formulations 
Comparison Drug Apparatus/Dose f2 
Low vs. High P USP 1 41.58 
USP 4 61.12 
R USP 2 42.24 
USP 4 35.39 
USP 1 vs. USP 4 P Low 34.08 
High 46.97 




Table 5: Criteria used for the selection of the best fit model, mean, n = 12 
Higuchi Korsmeyer-Peppas Hixson-Crowell Makoid-Banakar Weibull Logistic Gompertz 




0.8344 0.9905 0.9065 0.9915 0.9877 0.8475 0.7802 
P/High 0.7556 0.9862 0.9063 0.9896 0.9784 0.9123 0.8534 
R/low 0.9078 0.9093 0.9659 0.9938 0.9974 0.9473 0.9074 
R/High 0.6297 0.7972 0.9688 0.9584 0.9975 0.9542 0.9423 
AIC 
P/low 42.57 25.16 38.99 22.57 25.93 42.57 44.85 
P/High 43.39 25.13 37.14 22.12 27.18 37.67 40.91 
R/low 60.11 60.51 49.64 34.26 26.87 55.44 60.91 
R/high 67.35 62.79 44.11 48.54 20.14 47.79 50.43 




0.7692 0.9963 0.9459 0.9966 0.9968 0.9756 0.9436 
P/High 0.6859 0.9954 0.8889 0.9968 0.9886 0.9608 0.9218 
R/low 0.8255 0.8314 0.9153 0.9899 0.9981 0.9681 0.9485 
R/High 0.8565 0.8695 0.9286 0.9969 0.9994 0.9725 0.9808 
AIC 
P/low 41.70 16.95 32.58 16.66 14.93 28.26 33.68 
P/High 43.53 17.46 36.89 16.23 21.24 30.98 35.58 
R/low 68.56 68.95 61.93 43.16 28.21 53.05 57.91 
R/High 62.39 61.31 54.77 27.06 12.13 46.07 43.74 
 
Only dissolution profiles of two doses of propranolol-HCl with flow-
through cell method and dissolution profiles of low dose of ranitidine-
HCl, obtained with USP paddle apparatus and flow-through cell 
method, were similar (f2 = 50-100). Although USP Apparatuses 2 and 4 
have different characteristics (especially hydrodynamic condition) it 
should be noted that dissolution profiles of low dose of ranitidine-HCl 
are similar. Results suggest that dissolution performance of low dose 
of ranitidine-HCl is independent of the hydrodynamic environment to 
which tablets were subjected. 
Values of model-independent parameters: percentage of drug 
dissolved at last sampling time, MDT and DE of all formulations, are 
shown in table 3. Significant differences in all comparisons (Low vs. 
High dose) were found (*P<0.05) excepting percentage of ranitidine-
HCl dissolved at 45 min with USP paddle apparatus as well as the 
percentage of propranolol-HCl dissolved at 30 min and MDT of 
ranitidine-HCl with flow-through cell method. 
Model-dependent comparisons 
The t50%, t63.2%, and t85% values derived from the adjustment to 
hyperbole model are shown in table 3. Significant differences in all 
dissolution profiles of low vs. high dose, of both drugs, were found 
(*P<0.05). Dissolution data of USP basket or paddle apparatus vs. 
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flow-through cell were also compared and only dissolution profiles 
of low dose of ranitidine-HCl were similar (*P>0.05) which 
corroborates the independence of low dose of this drug of the 
hydrodynamic environment surrounding the tablets. 
Values of R2 adjusted and AIC obtained after the adjustment of 
dissolution data to all mathematical equations described above are 
shown in table 5. Considering the established criteria to choose the 
best fit model (highest R2 adjusted and lowest AIC) with USP vessels 
apparatus dissolution profiles of both doses of propranolol-HCl 
adjusted to Makoid-Banakar model and both doses of ranitidine-HCl 
adjusted to Weibull function. With the flow-through cell method 
both doses of ranitidine-HCl adjusted to Weibull model. Apparently, 
dissolution performance of both doses of ranitidine-HCl from the 
reference product can be explained with the same mathematical 
equation regardless of the dissolution system used. 
To compare dissolution profiles of propranolol-HCl and ranitidine-
HCl with the previous settings t50%, t75%, and t80% of propranolol-HCl 
(with USP basket apparatus data) were calculated and compared. 
Results are shown in table 6. Moreover, Weibull parameters of 
ranitidine-HCl (with both USP apparatuses data) were used to 
calculate the model-dependent parameter Td. Results are shown in 
table 7. 
Table 6: Time parameters after adjustment of propranolol-HCl data to Makoid-Banakar model, 
. 
mean±SEM, n = 12. *P<0.05,
Dose 
 low vs. high dose 
t50% t (min) 75% t (min) 80% (min) 
USP basket apparatus 
Low 13.15±0.26 20.48±0.35 21.91±0.36 
High 18.39±0.37* 25.88±0.45* 27.26±0.47* 
 
Table 7: Parameters after adjustment of ranitidine-HCl data to Weibull function. Mean, n = 12. *P<0.05,
Dose 
 low vs.  high dose 
α β Ti F Td (±SEM) max 
USP paddle apparatus 
Low 1980.87 1.78 -3.03 105.72 15.34±0.56 
High 7.81 0.94 2.14 105.24 8.53±0.16* 
Flow-through cell method 
Low 155557.80 3.54 -8.57 101.65 15.86±0.32 
High 598.82 2.14 -1.69 77.83 16.04±0.19 
 
Significant differences were found with t50%, t75%, and t80% data of 
propranolol-HCl (*P<0.05) meaning that dissolution profiles of low 
and high dose of propranolol-HCl, obtained with USP basket 
apparatus, were not similar while significant differences in Td values 
of ranitidine-HCl were found only with data obtained with USP 
paddle apparatus (*P<0.05). Dissolution profiles of ranitidine-HCl, 
obtained with USP paddle apparatus and flow-through cell method, 
were also compared and similar profiles were found only with the 
low dose. 
In this in vitro release study of low and high dose, data fitting to 
models previously described were carried out without any 
physiological significance in order to find a mathematical equation 
that explains the in vitro dissolution performance of propranolol-HCl 
and ranitidine-HCl from Mexican reference products. The purpose of 
using mathematical models to adjust dissolution data is that they 
facilitate the analysis and interpretation of observed results because 
they describe the dissolution profiles as a function of only a few 
parameters that can be statistically compared [30]. 
Form a scientific point of view propranolol-HCl is a candidate for 
granting a biowaiver when the immediate-release tablets are 
formulated with well-known excipients, show rapid in vitro 
dissolution, and meet the dissolution profile comparison criteria as 
defined in the Guidances (f2 = 50-100 in dissolution media with pH 
of physiological relevance). The USP criteria and method are suitable 
to assure batch to batch consistency [6]. On the other hand, it would 
be reasonably safe to grant biowaivers for ranitidine-HCl immediate-
release solid oral dosage forms, provided that the test product is 
formulated with some excipients, in amounts typically used in this 
kind of formulations, and the test product is also rapidly dissolving 
[7]. In this sense, the drug products used are commercial products of 
which the type of excipients and the manufacturing process are 
unknow, but for their safety and efficacy previously proven, they 
have been chosen by the Mexican Health Authorities as reference 
drug products to be used in bioequivalence studies. These products 
are also used for in vitro dissolution studies of generic formulations. 
The BCS suggests that for class I drugs and in some instances for 
class III drugs, 85% dissolution in 0.1 N HCl in 15 min can ensure 
that the bioavailability of the drug is not limited by dissolution. In 
these cases, the rate limiting step for drug absorption is gastric 
emptying [31]. Of all dissolution profiles obtained in this in vitro 
dissolution study, only high dose of ranitidine-HCl with USP paddle 
apparatus met this dissolution criterion. The mean t50% gastric 
residence (emptying) time is 15-20 min under fasting conditions. 
Based on this information, a conservative conclusion is that a drug 
product undergoing 85% dissolution in 15 min under mild 
dissolution test conditions in 0.1 N HCl behaves like a solution and 
generally should not have any bioavailability problems. If the 
dissolution is slower than gastric emptying, a dissolution profile 
with multiple points in multimedia is recommended [31]. On the 
other hand, for submission of a biowaiver request, an immediate-
release product (test and reference) should be rapidly dissolving 
(BSC class I) or very rapidly dissolving (BCS class III) [8]. Under 
pharmacopeial dissolution conditions used low dose of ranitidine-
HCl and all formulations with flow-through cell method do not 
comply with the requirement requested in the Guidance. 
This is the first in vitro dissolution study with reference tablets of 
propranolol-HCl and ranitidine-HCl using USP vessels apparatus and 
flow-through cell method since comparative dissolution profiles 
with two doses of reference products are scarce. This work reveals 
significant differences in dissolution rate and extent of two doses of 
each drug used. On the other hand, comparative dissolution studies 
between USP paddle apparatus and flow-through cell method have 
been reported with ibuprofen and carbamazepine generic 
suspensions [32, 33] with the aim of improving these dosage forms. 
Hydrodynamics of USP Apparatus 4 best simulates human 
gastrointestinal tract. Shah et al. [34] stated that in order to increase 
the ability to detect any changes in the manufacturing process, a 
dissolution test at a lower agitation rate is preferred. Attentions 
should be given to the conditions to which the ingested solid dosage 
forms may be exposed in the stomach. 
As dissolution data obtained with the flow-through cell method have 
been proved to better correlate with in vivo data [28, 35] and some 
pharmacopeial dissolution tests (that generally use USP vessels 
apparatus) do not allow to differentiate the rate and extent of in 
vitro release from generic drug products [36, 37] it is necessary to 
investigate new dissolution conditions that reflect the quality of 
generic formulations and estimate the in vivo performance of drugs. 
The quality of generic formulations depends on the available 
information of the dissolution performance of reference drug 
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products under different conditions (e. g. hydrodynamics or pH 
medium). From a quality assurance point of view, a more 
discriminative dissolution method is preferred, because the test will 
indicate possible changes in the quality of the product before in vivo 
performance is affected [31]. 
For multiple strengths of immediate-release products with linear 
kinetics, the bioequivalence study may be performed at the highest 
strength and waivers of in vivo studies may be granted on lower 
strengths, based on an adequate dissolution test, provided the lower 
strengths are proportionately similar in composition [31]. This 
assertion may not be an absolute rule especially if significant 
differences in dissolution performance of two doses of drugs with 
high solubility (class I or III) are documented. The search of 
“adequate dissolution test” must be essential for to ensure quality, 
safety and efficacy of drug products of any country. Some authors 
have reported that the effect of propranolol on portal pressure in 
patients with portal hypertension is highly variable and does not 
correlate with propranolol racemate or stereoisomer plasma 
concentrations [38]. Differences on in vitro behavior found in this 
work could explain in vivo performance of propranolol. 
It is important to consider bioequivalence data of the drugs used in 
this work. Polli [39] reported the association of dissolution rate of 
three ranitidine-HCl tablets and their bioequivalences relative to the 
reference product. He found all formulations bioequivalent despite 
differences in dissolution rates. The author asserts that differences 
in dissolution rates observed earlier than 30 min had negligible 
consequences in vivo. It is necessary to carry on IVIVC studies with 
both doses of propranolol-HCl and ranitidine-HCl to evaluate the 
predictability of the proposed methodology since if problems are 
reported with reference drug products the quality of generic 
formulations will be affected. 
CONCLUSION 
In vitro dissolution performance of two doses of propranolol-HCl 
and ranitidine-HCl under the hydrodynamic environment of USP 
basket or paddle apparatus and the flow-through cell was not 
expected. It is essential to carry out bioequivalence studies with the 
lowest and highest doses of reference products used. This action 
seems not to be necessary for class I and III drugs, however, due to 
the results obtained in the present work it must be confirmed that 
significant differences in dissolution profiles do not affect the 
bioequivalence of both doses. 
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